Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Add filters

Year range
Rev. Assoc. Med. Bras. (1992) ; 66(9): 1180-1186, Sept. 2020. tab, graf
Article in English | LILACS, SES-SP | ID: biblio-1136360


SUMMARY INTRODUCTION: The vascular evaluation of the erectile function through Color Duplex-Doppler Ultrasound (CDDU) of the penis can benefit the therapeutic decision-making process. Unfortunately, there is no standard procedure for CDDU conduction, a fact that results in high result-interpretation variability. OBJECTIVE: The aims of this review are to promote greater standardization during CDDU of the penis and discuss the fundamental principles for its accurate conduction. METHODS: CDDU is initially conducted with the penis in the flaccid state; the whole penis must be assessed (images at B mode) with a high-frequency linear transducer (7.5-18 MHz). Intracavernous injection of vasodilating agents (prostaglandin E1, papaverine, phentolamine) is performed to induce a rigid erection. Serial measurements at different times should be taken during the CDDU session and penile rigidity must be assessed in each evaluation. RESULTS: It is important to monitor the erection response after the vasoactive agent (hardness scale), and scanning during the best-quality erection should be contemplated. Manual self-stimulation, audiovisual sexual stimulation (AVSS), and vasoactive agent re-dosing protocols must be taken into account to reduce the influence of psychogenic factors and to help the patient to get the hardest erection possible. Such measurements contribute to the maximal relaxation of the erectile tissue, so the hemodynamic parameters are not underestimated. CONCLUSIONS: CDDU is a relevant specialized tool to assess patients with erectile dysfunction; therefore, this guideline will help to standardize and establish uniformity in its conduction and interpretation, taking into consideration the complexity and heterogeneity of CDDU evaluations of the penis.

RESUMO INTRODUÇÃO: A avaliação vascular da função erétil por meio da ultrassonografia com Doppler colorido do pênis (UDCP) pode trazer benefícios na tomada de decisão. Infelizmente, a falta de padronização na condução de UDCP resulta em alta variabilidade do exame, além de poder comprometer a interpretação dos resultados. OBJETIVO: Os objetivos desta revisão são promover uma maior padronização durante o UDCP e discutir os princípios fundamentais para sua correta condução e interpretação. MÉTODOS: O UDCP é conduzido inicialmente com o pênis no estado flácido; todo o pênis deve ser avaliado (imagens no modo B) com um transdutor linear de alta frequência (7,5-18 MHz). A injeção intracavernosa de agentes vasodilatadores (prostaglandina E1, papaverina, fentolamina) é realizada para induzir uma ereção rígida. Medições seriais em momentos diferentes podem ser realizadas durante a sessão da UDCP e a rigidez peniana deve ser estimada em cada avaliação. RESULTADOS: É importante monitorar a resposta da ereção após o agente vasoativo (escala de rigidez), bem como realizar avaliação hemodinâmica durante a ereção de melhor qualidade. Os protocolos de estimulação sexual manual e audiovisual (AVSS) e redosagem de agente vasoativo devem ser levados em consideração para reduzir a influência de fatores psicogênicos e ajudar o paciente a obter a ereção mais rígida possível. Tais medidas contribuem para o relaxamento máximo do tecido erétil, de modo que os parâmetros hemodinâmicos não são subestimados. CONCLUSÕES: O UDCP é uma ferramenta especializada relevante para avaliar pacientes com disfunção erétil; portanto, esta diretriz ajudará a padronizar e estabelecer uniformidade em sua condução e interpretação, se considerarmos a complexidade e a heterogeneidade das avaliações do pênis por UDCP

Humans , Male , Penis , Penile Erection , Ultrasonography, Doppler, Color , Hemodynamics , Erectile Dysfunction
Clinics ; 74: e713, 2019. tab, graf
Article in English | LILACS | ID: biblio-989633


OBJECTIVES: To assess the prevalence and interrelationship between lower urinary tract symptoms and sexual dysfunction in men with multiple sclerosis (MS). METHODS: In a cross-sectional study, we evaluated 41 men (mean age 41.1±9.9 years) with MS from February 2011 to March 2013, who were invited to participate irrespective of the presence of lower urinary tract symptoms or sexual dysfunction. Neurological impairment was assessed with the Expanded Disability Status Scale; lower urinary tract symptoms were evaluated with the International Continence Society male short-form questionnaire, and sexual dysfunction was evaluated with the International Index of Erectile Function. All patients underwent transabdominal urinary tract sonography and urine culture. RESULTS: The mean disease duration was 10.5±7.3 years. Neurological evaluation showed a median Expanded Disability Status Scale score of 3 [2-6]. The median International Continence Society male short-form questionnaire score was 17 [10-25]. The median International Index of Erectile Function score was 29 [15-46]. Twenty-nine patients (74.4%) had sexual dysfunction as defined by an International Index of Erectile Function score <45. Voiding dysfunction and sexual dysfunction increased with the degree of neurological impairment (r=0.02 [0.02 to 0.36] p=0.03 and r=-0.41 [-0.65 to -0.11] p=0.008, respectively). Lower urinary tract symptoms and sexual dysfunction also displayed a significant correlation (r=-0.31 [-0.56 to -0.01] p=0.04). CONCLUSIONS: Most male patients with MS have lower urinary tract symptoms and sexual dysfunction. The severity of the neurological disease is a predictive factor for the occurrence of voiding and sexual dysfunctions.

Humans , Male , Adult , Middle Aged , Aged , Young Adult , Sexual Dysfunction, Physiological/epidemiology , Lower Urinary Tract Symptoms/epidemiology , Multiple Sclerosis/epidemiology , Quality of Life , Sexual Dysfunction, Physiological/complications , Sexual Dysfunction, Physiological/diagnosis , Severity of Illness Index , Brazil/epidemiology , Prevalence , Cross-Sectional Studies , Surveys and Questionnaires , Urinary Bladder, Overactive/complications , Lower Urinary Tract Symptoms/complications , Lower Urinary Tract Symptoms/diagnosis , Erectile Dysfunction/complications , Multiple Sclerosis/complications , Multiple Sclerosis/diagnosis
Int. braz. j. urol ; 44(1): 172-179, Jan.-Feb. 2018. tab, graf
Article in English | LILACS | ID: biblio-892958


ABSTRACT Purpose To assess the impact of sperm retrieval on the gonadal function of rats with impaired spermatogenesis by comparing testicular sperm extraction (TESE) to aspiration (TESA). The efficacy of these procedures to sperm obtainment was also compared. Materials and Methods A pilot study showed impaired spermatogenesis, but normal testosterone (T) production after a bilateral orchidopexy applied to 26 rats, which were randomly assigned into four groups: TESE (n=7), TESA (n=7), SHAM (n=6) and Control (n=6). The T levels were measured through comparative analysis after the orchidopexy. Results There was no statistical difference in the animal's baseline T levels after orchidopexy in comparison to the controls: the TESE and TESA groups, 6.66±4.67ng/mL; the SHAM group (orchidopexy only), 4.99±1.96ng/mL; and the Control, 4.75±1.45ng/mL, p=0.27. Accordingly, no difference was found in the postoperative T levels: TESE, 5.35±4.65ng/mL; TESA, 3.96±0.80ng/mL; SHAM, 3.70±1.27ng/mL; p=0.4. The number of sperm cells found through TESE (41.0±7.0) was significantly larger than that found through TESA (21.3±8.1, p=0.001). Moreover, higher tissue weight was found through TESE (0.09±0.02g versus 0.04±0.04g, p=0.04). Conclusions The testicular sperm capture performed in rats through extraction or aspiration, after orchidopexy, did not significantly decrease the T levels. The amount of sperm found through testicular sperm extraction was higher than that through testicular sperm aspiration.

Animals , Male , Rats , Sperm Motility/physiology , Spermatogenesis/physiology , Spermatozoa/physiology , Testis/physiology , Sperm Retrieval/adverse effects , Testis/surgery , Testosterone/biosynthesis , Random Allocation , Pilot Projects , Rats, Wistar , Models, Animal , Orchiopexy/methods
Br J Med Med Res ; 2015; 10(2): 1-8
Article in English | IMSEAR | ID: sea-181706


Aims: Symptoms associated with renal cell carcinoma characterize high-risk disease. Hematuria is the most common symptom and usually occurs as a result of urothelial invasion. The objective of this study was to evaluate the prognostic value of progressive symptomatic disease in patients with kidney cancer. Place and Duration of Study: Sao Paulo Cancer Institute at University of Sao Paulo School of Medicine between 2005 and 2009. Methodology: Data was prospectively recorded at our database and retrospectively reviewed. Sixty-six individuals who presented with macroscopic hematuria were included in our analysis. Patients were divided into three groups: (1) Exclusive hematuria (27 patients), (2) Hematuria associated with another symptom (23 patients), and (3) Hematuria associated with two or more symptoms. We evaluated these groups for histopathology, kidney function, recurrence, and survival characteristics. Results: Mean tumor diameter was 8.5 cm, 11 cm and 13.4 cm for groups (1), (2) and (3). Recurrence-free survival was 89%, 91%, and 69% and overall survival was 96%, 79%, and 56% for groups (1), (2) and (3), respectively. The mean follow-up time was 97.6 months and the disease-free survival rate was 84.8%. Cox regression analysis showed a death risk 10.5 times higher in group (3) when compared to Group (1). Conclusion: Association of two or more symptoms with hematuria impairs prognosis of patients surgically treated for kidney cancer.